AIM
BCRX icon

Aigen Investment Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Aigen Investment Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-28,058
Closed -$219K – 532
2025
Q4 		$219K Sell
28,058
-72,345
-72% -$523K 0.05% 456
2025
Q3 		$762K Buy
100,403
+47,598
+90% +$396K 0.12% 266
2025
Q2 		$473K Buy
+52,805
New +$492K 0.06% 413
2024
Q4 		– Sell
-28,661
Closed -$218K – 735
2024
Q3 		$218K Buy
28,661
+12,280
+75% +$93.3K 0.04% 559
2024
Q2 		$101K Sell
16,381
-24,720
-60% -$136K 0.02% 699
2024
Q1 		$209K Buy
41,101
+28,431
+224% +$160K 0.05% 536
2023
Q4 		$75.9K Sell
12,670
-140,804
-92% -$816K 0.01% 740
2023
Q3 		$1.09M Buy
153,474
+75,179
+96% +$540K 0.2% 146
2023
Q2 		$551K Buy
78,295
+35,772
+84% +$287K 0.08% 326
2023
Q1 		$355K Buy
+42,523
New +$409K 0.05% 392
2022
Q2 		– Sell
-11,172
Closed -$182K – 530
2022
Q1 		$182K Buy
+11,172
New +$179K 0.03% 473
2021
Q2 		– Sell
-21,588
Closed -$220K – 475
2021
Q1 		$220K Buy
+21,588
New +$223K 0.03% 514
2020
Q3 		– Sell
-13,984
Closed -$67K – 858
2020
Q2 		$67K Buy
+13,984
New +$55.8K 0.01% 770

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Aigen Investment Management's BCRX Position: Q1 2026 in Review

Aigen Investment Management sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2026, closing a stake of 28,058 shares — an estimated $219K sold.

Aigen Investment Management first reported a position in BCRX in Q2 2020 and held it in 13 quarters. The position peaked at $1.09M in Q3 2023. 302 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Aigen Investment Management reported no remaining BioCryst Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Aigen Investment Management sold 28,058 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $219K.
  • Aigen Investment Management first reported a position in BioCryst Pharmaceuticals in Q2 2020 and held it in 13 quarters.
  • Aigen Investment Management's BioCryst Pharmaceuticals position peaked at $1.09M in Q3 2023.
  • 302 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Aigen Investment Management's 13F filing for Q1 2026, filed 15 May 2026.